Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions

a fibrotic, inflammatory and neovascularization technology, applied in the field of ocular disorders, can solve the problems of insufficient treatment options, complex search for effective treatments, and unclear amd exact etiology and pathogenesis, so as to reduce or prevent aberrant fibrogenesis, fibrosis or scarring, and modulate surgical and traumatic wound healing responses of the eye.

Inactive Publication Date: 2007-06-28
LPATH
View PDF99 Cites 51 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention provides methods for treating ocular diseases or conditions by administering a pharmaceutical composition containing an immune-derived moiety that targets a bioactive lipid. This helps decrease the concentration of the lipid and prevent its negative effects. The immune-derived moiety can be a monoclonal antibody or fragment thereof, and can be reactive against lysolipids such as S1P or LPA. The pharmaceutical composition can be administered through various routes, such as systemic injection, transdermal delivery, or intraocular or periocular injection. The invention also includes the use of immune-derived moieties in the treatment of scleroderma. The technical effects of the invention include reducing the concentration of bioactive lipids and preventing their negative effects, inhibiting aberrant fibrogenesis, inflammation, and neovascularization, and modulating surgical and traumatic wound healing responses of the eye."

Problems solved by technology

Multiple theories exist but, the exact etiology and pathogenesis of AMD are still not well understood.
The multiple cellular and cytokine interactions which are associated with exudative AMD greatly complicate the search for effective treatments.
While CNV and edema are manageable in part by anti-VEGF therapeutics, potential treatments to mitigate scar formation and inflammation have not been adequately addressed [Bylsma and Guymer (2005), Clin Exp Optom, vol 88: 322-34 and Pauleikhoff (2005), Retina, vol 25: 1065-84].
The results in a larger patient population may be less robust.
Tissue damage can result from either component.
These other aspects of the pathologic process are not addressed by current anti-VEGF treatments.
However, new vessels when uncontrolled, are commonly defective and promote leakage, hemorrhaging and inflammation.
The formation of subretinal fibrosis leads to irreversible damage to the photoreceptors and permanent vision loss.
Because regulation of various cellular processes involving S1P has particular impact on neuronal signaling, vascular tone, wound healing, immune cell trafficking, reproduction, and cardiovascular function, among others, it is believed that alterations of endogenous levels of S1P within these systems can have detrimental effects, eliciting several pathophysiologic conditions, including cancer, heart failure, ocular disease and infectious and autoimmune diseases.
Finally, S1P may modulate the maturation of naive vasculature, a process leading to a loss of sensitivity to anti-angiogenic agents.
As will be appreciated, it is not always possible to distinguish between “preventing” and “suppressing” a disease or disorder since the ultimate inductive event or events may be unknown or latent.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions
  • Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions
  • Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions

Examples

Experimental program
Comparison scheme
Effect test

example 1

SPHINGOMAB Significantly Reduced CNV and Scar Formation in a Murine Model of CNV

[0136] Female C57BL6 / J mice were subjected to laser-induced rupture of Bruch's membrane and administered either 0.5 μg of Sphingomab or an isotype-matched non-specific (NS) antibody diluted in 2 μl of physiological saline. Mice were sacrificed 14 and 28 days after laser rupture.

[0137] To induce CNV lesions, the pupils were dilated with ophthalmic tropicamide (0.5%) and phenylephrine (2.5%). A coverslip was placed on the eye. An Oculight GL 532 nm (Iridex Corporation, Mountain View, Calif.) coupled to a slit lamp set to deliver a 100 msec pulse at 150 mW with a 50 μm spot size was used to rupture Bruch's membrane in three quadrants of the right eye located approximately 50 μm from the optic disc at relative 9, 12 and 3 o'clock positions. The left eye served as an uninjured control in all cases. Any lesion not associated with a vapor bubble or lesions that became confluent were excluded from analysis.

[0...

example 2

SPHINGOMAB Inhibits Neovascularization Through Multiple Mechanisms Including Inhibition of Endothelial Cell Migration and Tube Formation

[0141] S1P promotes the migration of human umbilical vein endothelial cells (HUVECs) and, in Matrigel and other assays, the formation of de novo BV formation in vitro [112]; SPHINGOMAB can neutralize these effects of S1P. Experiments were performed as described by Visentin et al. (Cancer Cell 2006 March;9(3):225-38). Data in FIG. 2A suggest that HUVECs seeded onto GF-reduced Matrigel formed multiple capillary-like structures in the presence of S1P and failed to form capillary-like structures in the absence of S1P or when co-incubated with SPHINGOMAB and S1P. Data in FIG. 2B demonstrate the potent ability of 0.1-1 μM S1P to stimulate HUVEC migration 2-2.5 fold over non-treated HUVECs, or HUVECs co-incubated with SPHINGOMAB in a Matrigel chemoinvasion assay. Combined, these studies demonstrate that SPHINGOMAB can efficiently mitigate the pro-angiogen...

example 3

SPHINGOMAB Inhibits Neovascularization Through Multiple Mechanisms Including Mitigation of the Effects of S1P, VEGF and bFGF in vivo

[0142] Based on in vivo studies showing that SiP increased endothelial capillary growth into subcutaneously implanted Matrigel plugs[54], we speculated that SPHINGOMAB could reduce de novo BV formation in vivo. To investigate this, we employed the in vivo Matrigel Plug assay for neovascularization. In one set of experiments, Matrigel was supplemented with either 1 μM S1P, 0.5 μg / mL bFGF or 1 μg / mL VEGF and then injected I.P. into mice (n=4). After 10 days, the mice were heparinized and injected with the fluorescent lectin, Isolectin B4-FITC, which binds to adhesion molecules expressed by vascular EC that form the growing BVs. The plugs were then excised, frozen in OCT, sectioned and viewed for FITC-stained BVs. Data in FIG. 3A suggest that S1P is a more potent stimulator of neovascularization in vivo than bFGF or VEGF[Lee, et al., (1999), Biochem Bioph...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
spot sizeaaaaaaaaaa
Login to View More

Abstract

The present invention relates to compositions and methods for prevention and treatment of diseases and conditions, including ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation and / or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against bioactive lipids and which are capable of decreasing the effective concentration of said bioactive lipid. In some embodiments, the immune-derived moiety is a monoclonal antibody that is reactive against sphingosine-1-phosphate (S1P) or lysophosphatidic acid (LPA).

Description

RELATED APPLICATIONS [0001] This application claims priority to, the benefit of, and incorporates by reference for all purposes the following patent-related documents, each in its entirety: U.S. provisional patent application Ser. No. __ / ______ [attorney docket no LPT-3010-PV, entitled “Compositions and Methods for Binding Sphingosine-1-Phosphate”], and U.S. provisional patent application Ser. No. __ / ______ [attorney docket no LPT-3020-PV, entitled “Humanized Antibodies to Sphingosine-1-Phosphate in the Treatment of Ocular Disorders”], both filed concurrently with the instant application; U.S. provisional patent application Ser. No. __ / ______ [attorney docket no LPT-3100-PV2], filed 12 Aug., 2006, and U.S. patent application Ser. No. 11 / 261,935, filed 28 Oct., 2005, of which this application is a continuation-in-part.TECHNICAL FIELD [0002] The present invention relates to methods of treatments for ocular disorders using immune-derived moieties which are reactive against bioactive li...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395
CPCA61K31/685A61K2039/505C07K16/18C07K16/3076C07K2316/96C07K2317/24C07K2317/73C07K2317/92A61P3/10A61P9/10A61P17/00A61P27/02A61P29/00A61P31/22A61P33/00A61P37/02A61P37/06A61P43/00C07K2317/76
Inventor SABBADINI, ROGER A.GARLAND, WILLIAM A.STOLLER, GLENN L.
Owner LPATH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com